Pricing Log in Create free account

AC Immune (ACIU) vs Cabaletta Bio, Inc. (CABA)

AC Immune and Cabaletta Bio, Inc. are both Biotechnology companies. AC Immune and Cabaletta Bio, Inc. are of similar size ($262.8M and $249.4M). Cabaletta Bio, Inc. has the higher net margin (0.00% vs −1,783.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Cabaletta Bio, Inc. leads on 6 and AC Immune on 5.

Valuation

Metric ACIU CABA Biotechnology median
P/E n/m n/m 8.50
P/S 50.83 n/m 9.71
P/B 5.30 1.01 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.07 0.64
EV/Sales 31.31 n/m 9.21
Earnings yield (34.31%) (111.35%) (33.15%)
Free cash flow yield (35.48%) (72.80%) (25.50%)

Profitability

Metric ACIU CABA Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (1,745.75%) 0.00% 0.00%
Net margin (1,783.66%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (93.20%) (56.36%)
Return on assets 0.00% (75.36%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ACIU CABA Biotechnology median
Revenue growth (TTM) (85.56%) — 6.02%
EPS growth (last fiscal year) (44.83%) 10.26% 30.26%
Revenue growth, 5-year CAGR (47.84%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACIU CABA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.93 5.79 4.72
Net debt to EBITDA 1.37 0.84 0.96

Dividend

Metric ACIU CABA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ACIU CABA Biotechnology median
Market cap 249.35m 262.79m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack